Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men

Circulation

Volumn 91, Issue 2, 1995, Pages 265-269

  Stengård, Jari H ^a,b   Zerba, Kim E ^b   Pekkanen, Juha ^a   Ehnholm, Christian ^a   Nissinen, Aulikki ^c   Sing, Charles F ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

apolipoproteins; coronary disease; mortality

Indexed keywords

APOLIPOPROTEIN E; LIPID;

AGED; ALLELE; ARTICLE; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FINLAND; GENOTYPE; HEART DEATH; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MALE; MORTALITY; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR;

EID: 0028832051     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.91.2.265     Document Type: Article

References (35)

1. Pekkanen J. Coronary heart disease during a 25-year follow-up: risk factors and their secular trends in the Finnish cohorts of the Seven Countries study. Helsinki, Finland: National Board of Health; 1987. Thesis.
2. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993;87(suppl II):II-3-II-16.
3. Dawber TR. The Framingham Study. Cambridge, Mass: Harvard University Press; 1980.
4. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In: Born GVR, Schwartz CJ, eds. New Horizons in Coronary Heart Disease. London, UK: Science Press Ltd; 1993:5.1-5.21.
5. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
6. Utermann G, Pruin N, Steinmetz A. Polymorphism of apolipoprotein E, III: effect of a single polymorphic gene locus on plasma lipid levels in man. Clin Genet. 1979;15:63-72.
7. Xhignesse M, Lussier-Cacan S, Sing CF, Kessling AM, Davignon J. Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. Arterioscler Thromb. 1991;11:1100-1110.
8. Kaprio J, Ferrell RE, Kottke BA, Kamboh MI, Sing CF. Effects of polymorphisms in apolipoproteins E, A-IV, and H on quantitative traits related to risk for cardiovascular disease. Arterioscler Thromb. 1991;11:1330-1348.
9. Boerwinkle E, Visvikis S, Welsh D, Steinmetz J, Hanash SM, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man: II, the role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Genet. 1987;27:567-582.
10. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71:160-165.
11. Cumming AM, Robertson FW. Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet. 1984;25:310-313.
12. Kuusi T, Nieminen MS, Ehnholm C, Yki-Järvinen H, Valle M, Nikkilä EA, Taskinen M-R. Apoprotein E polymorphism and coronary artery disease: increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis. 1989;9:237-241.
13. Nieminen MS, Mattila KJ, Aalto-Setälä K, Kuusi T, Kontula K, Kauppinen-Mäkelin R, Ehnholm C, Jauhiainen M, Valle M, Taskinen M-R. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb. 1992;12:58-69.
14. Barrett-Connor E, Suarez L, Khaw K-T, Criqui MH, Wingard DL. Ischemic heart disease risk factors after age 50. J Chron Dis. 1984;37:903-908.
15. Stavenow L, Elmståhl S, Jerntorp P, Nilsson-Ehle P, Pessah-Rasmussen H, Galvard H, Hansen F, Samuelsson S-M. Eighty-year old men without cardiovascular disease in the community of Malmö: part 1, social and medical factors, with special reference to the lipoprotein pattern. J Int Med. 1990;228:9-15.
16. Jacobsen SJ, Freedman DS, Hoffmann RG, Gruchow HW, Anderson AJ, Barboriak JJ. Cholesterol and coronary artery disease: age as an effect modifier. J Clin Epidemiol. 1992;45:1053-1059.
17. Keys A. Coronary heart disease in seven countries. Circulation. 1970;41(suppl I):I-1-I-211.
18. Keys A, Aravanis C, Blackburn HW, van Buchem FSP, Buzina R, Djordjevic BS, et al. Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Med Scand. 1967;460(suppl):1-392.
19. Nissinen A, Kivelä S-L, Pekkanen J, Tuomilehto J, Kostiainen E, Piippo H, et al. Levels of some biological risk indicators among elderly men in Finland. Age Aging. 1986;15:203-211.
20. Nissinen A, Tervahauta M, Pekkanen J, Kivinen P, Stengärd J, Kaarsalo E, et al. Prevalence and change of cardiovascular risk factors among men born 1900-19: the Finnish cohorts of the Seven Countries Study. Age Ageing. 1993;22:365-376.
21. World Health Organization. Arterial Hypertension. Geneva, Switzerland: World Health Organization; 1978, Technical Report Series no 628.
22. Kostner GM. Enzymatic determination of cholesterol in HDL fractions prepared by polyanion precipitation. Clin Chem. 1976;22:695.
23. Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res. 1987;28:455-463.
24. Ehnholm C, Lukka M, Kuusi T, Nikkilä E, Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 1986;27:227-235.
25. SAS Institute. SAS User's Guide: Statistics. Cary, NC: SAS Institute Inc; 1985.
26. Stuyt PMJ, Brenninkmeijer BJ, Demacker PNM, Hendriks JCM, van Elteren P, Stalenhoef AFH, van't Laar A. Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease. Scand J Clin Lab Invest. 1991;51:425-435.
27. Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol and coronary artery disease. Clin Chem. 1986;32:778-781.
28. Marshall HW, Morrison LC, Wu LL, Anderson JL, Corneli PS, Stauffer DM, Allan A, Karagounis LA, Ward RH. Apolipoprotein polymorphisms fail to define risk of coronary artery disease: results of a prospective, angiographically controlled study. Circulation. 1994;89:567-577.
29. Utermann G, Jaeschke M, Menzel J. Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEBS Lett. 1975;56:352-355.
30. Kameda K, Matsuzawa Y, Kubo M, Ishikawa K, Maejima I, Yamamura T, Yamamoto A, Tarui S. Increased frequency of lipoprotein disorders similar to type III hyperlipoproteinemia in survivors of myocardial infarction in Japan. Atherosclerosis. 1984;51:241-249.
31. Sing CF, Reilly SL. Genetics of common diseases that aggregate, but do not segregate. In: Sing CF, Hanis CL, eds. Genetics of Cellular, Individual, Family, and Population Variability. New York, NY: Oxford University Press; 1993:140-161.
32. Davignon J, Roederer G, Trudeau P, Dallongeville J, Sing CF. Atherogenic dyslipidemias: disorders of apolipoprotein E isoforms. In: Crepaldi G, Gotto AM, Manzato E, Gaggio G, eds. Atherosclerosis VIII. Netherlands: Elsevier Science Publishers; 1989:389-393.
33. Reilly SL, Ferrell RE, Kottke BA, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minnesota: II, regression relationships with concomitants. Am J Hum Genet. 1992;51:1311-1324.
34. Schächter F, Faure-Delanef L, Guénot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nature Genet. 1994;6:29-32.
35. Lehtimäki T, Moilanen T, Viikari J, Åkerblom HK, Ehnholm C, Rönnemaa T, Marniemi J, Dahlen G, Nikkari T. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res. 1990;31:487-495.